HBV ‐Induced Carcinogenesis: Mechanisms, Correlation With Viral Suppression, and Implications for Treatment
Liver International · 2025-01 · 45 (1)
DOI: 10.1111/liv.16202 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Liver International, online erschienen am 25.12.2024. Verfasst von Thomas Tu und 2 weiteren Autor:innen. Beteiligte Einrichtung: Storr Liver Centre, Westmead Clinical School, Centre for Infectious Diseases and Microbiology and Westmead Institute for Medical Research, The Univer…. Hauptthemen laut MEDLINE: Hepatitis B, Chronic, Liver Neoplasms, Carcinoma, Hepatocellular, Antiviral Agents. Die Arbeit wurde bisher 28-mal zitiert (Crossref) und nennt 148 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Chronic hepatitis B virus (HBV) infection is a common but underdiagnosed and undertreated health condition and is the leading cause of hepatocellular carcinoma (HCC) worldwide. HBV (rated a Grade 1 carcinogen by the International Agency for Research on Cancer) drives the transformation of hepatocytes in multiple ways by inducing viral DNA integrations, genetic dysregulation, chromosomal translocations, chronic inflammation, and oncogenic pathways facilitated by some HBV proteins. Importantly, these mechanisms are active throughout all phases of HBV infection. Nevertheless, most clinical guidelines for antiviral therapy recommend treatment based on a complex combination of HBV DNA levels, transaminasemia, liver histology, and demographic factors, rather than prompt treatment for all people with infection.
Aims
To determine whether current antiviral treatment frameworks address the impacts of chronic HBV infection, particularly in preventing cancer development. Materials and Methods We reviewed recent data demonstrating that antiviral therapy can inhibit pro‐oncogenic factors acting throughout a chronic HBV infection.
Results
We conducted an extensive review of Hepatitis B virology data and correlating clinical outcomes based on these findings we propose simplifying and expanding treatment initiation to reduce the incidence of new infections, prevent progression of liver disease, and lower the risk of hepatocellular carcinoma. Additionally, we draw insights from other blood‐borne pathogens, emphasizing the benefits of antiviral treatment in preventing transmission, reducing stigma, and reframing treatment as a strategy for cancer prevention.
Conclusion
Incorporating these practice changes into treatment is likely to reduce the overall burden of chronic HBV infections and HCC. Through this, we may better achieve the World Health Organization's goal of eliminating viral hepatitis as a public health threat and minimise its impact on people's lives.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Storr Liver Centre, Westmead Clinical School, Centre for Infectious Diseases and Microbiology and Westmead Institute for Medical Research, The University of Sydney, Sydney, New South Wales, Australia.
- Gilead Sciences Inc., Provincetown, Massachusetts, USA.
- NYU Langone Health, New York, New York, USA.
ORCID-Profile: Thomas J McQuaid
Zitieren
APA
Tu, T., McQuaid, T. J., & Jacobson, I. M. (2025). HBV ‐Induced Carcinogenesis: Mechanisms, Correlation With Viral Suppression, and Implications for Treatment. Liver International, 45(1). https://doi.org/10.1111/liv.16202
Vancouver
Tu T, McQuaid TJ, Jacobson IM. HBV ‐Induced Carcinogenesis: Mechanisms, Correlation With Viral Suppression, and Implications for Treatment. Liver International. 2025;45(1). doi:10.1111/liv.16202
BibTeX
@article{Tu2025,
author = {Tu, Thomas and McQuaid, Thomas J and Jacobson, Ira M},
title = {HBV ‐Induced Carcinogenesis: Mechanisms, Correlation With Viral Suppression, and Implications for Treatment},
journal = {Liver International},
year = {2025},
volume = {45},
number = {1},
doi = {10.1111/liv.16202}
}
EUVIMED